Funding Alert｜Pathos AI Raises $237M Series E — BMS Trades Equity for Platform Access as Valuation Nearly Doubles in 17 Months
Pathos AI closed a $237M Series E led by Bristol Myers Squibb, pushing its valuation to $3B — just 17 months after Series D valued it at $1.6B. The signal: BMS isn't making a purely financial bet. It's trading equity for portfolio-wide access to the Pathos Foundry platform plus a three-year exclusive in neuroscience — pharma is starting to treat investing in AI biotech as a shortcut to acquiring in-house agent capability.